C
2197
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Clover Biopharmaceuticals Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +497% compared to the Hang Seng (Hong Kong)'s +16% growth.
Stocks Performance
2197 vs Hang Seng (Hong Kong)
Performance Gap
2197 vs Hang Seng (Hong Kong)
Performance By Year
2197 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Clover Biopharmaceuticals Ltd
Glance View
Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 814 full-time employees. The company went IPO on 2021-11-05. The firm's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The firm's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.